On Monday, the Subject Expert Commitee of Central Drugs Standard Control Organisation (CDSCO) recommended granting permission to manufacture and market the anti-Covid pill Molnupiravir for limited emergency use in adult patients with SpO2 of 93 % and a high risk of disease progression, including admission to hospital or death, subject to certain conditions.
All the recommendations have been sent to the Drugs Controller General of India for final clearance.
The SEC on Covid-19 of the CDSCO, which examined the EUA application of Serum Institute of India for the second time on Monday, has recommended granting EUA to Covovax. The SEC also proposed granting permission to produce and commercialise Molnupiravir, an anti-Covid tablet, for limited emergency use in adult Covid patients with a SpO2 of 93 % and a high risk of disease progression, subject to certain conditions.
Dr Reddy’s Laboratories, in collaboration with Cipla, Mylan, Torrent, Emcure, and Sun Pharma had submitted a proposal for approval of Molnupiravir 200mg capsules for emergency use.
Post Your Comments